News

The company has established substantive cooperation with Pure Biologics S.A., a biopharmaceutical company. The two entities will cooperate in the field of research and development on biotechnological drugs, which will result in the identification of potential biotech drug candidates, which Celon Pharma will subsequently be developing in preclinical and clinical areas. Maciej Wieczorek, PhD, CEORead more »

Information of the Management Board of Celon Pharma S.A. Nationwide voluntary and preventive withholding of Valzek (80 mg and 160 mg). With regard to the decisions of the Chief Pharmaceutical Inspector, on 21 August 2018 the Board of the Celon Pharma S.A. announces that the decisions had been issued at the Company’s request. The undertakenRead more »

With regard to the decisions of the Chief Pharmaceutical Inspector, on 21 August 2018 the Board of the Celon Pharma S.A. announces that the decisions had been issued at the Company’s request. The undertaken actions constitute a response to a global market situation regarding the active ingredient valsartan.. These steps are preventive in nature and areRead more »

Information of the Management Board of Celon Pharma S.A.. The Management Board of Celon Pharma S.A. announced that on 10 August 2018 the Chief Pharmaceutical Inspector repealed its decision No. 4/WS/2018 of 21.06.2018 on the voluntary, temporary withholding of one batch of Salmex, (500 µg + 50 µg), number 223020018. The results of tests conducted onRead more »

At the end of May, the prestigious scientific journal European Journal of Medicinal Chemistry published an article of researchers from our R&D Division: Rafał Moszczyński-Petkowski, Jakub Majer, Małgorzata Borkowska, Łukasza Bojarski, Sylwia Janowska, Mikołaj Matłoka, Filip Stefaniak, Damian Smuga, Katarzyna Bazydło, Krzysztof Dubiel and Maciej Wieczorek. The publication’s subject is: Synthesis and characteristics of two newRead more »

On 20 June 2018, Celon Pharma S.A. has submitted an application to the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products for the consent to commence the next stage of the trial, i.e. the clinical phase. A decision in this matter should be issued within 60 days. The second phase of clinicalRead more »

On 24 June 2018, representatives of Celon Pharma’s Metabolic Disorders Research Group will take part in a poster session, during which they will make a presentation on the following subject: Discovery of CPL207-280ca, an effective and safe GPR40 agonist for the treatment of type 2 diabetes. The conference is the world’s largest event bringing together researchers,Read more »

Salmex received marketing authorisation on another foreign market – in Honduras – it will be marketed under the name Ventiflu Discus. The marketing authorisation process was intermediated by the Company’s business partner under a commercial agreement. Honduras is another market in Central America, after Guatemala and El Salvador, where the Company has registered its product.Read more »

President of the Management Board of Celon Pharma S.A. was appointed a member of the jury for the 14th edition of the Polish President’s Economic Award. Maciej Wieczorek joined the interdisciplinary group of experts representing business, science, media, non-governmental organisations and capital market institutions, who will nominate companies for the Polish President’s Economic Award. ThisRead more »

Between 4 and 7 June this year, representatives of our Company are taking part in the largest global Life Sciences networking meeting. Our participation at this event is one of the elements of our implementing our strategy to increase Celon Pharma’s international presence and our planned global commercialisation of the Company’s innovative portfolio. Bogdan Manowski, DirectorRead more »